In this webinar, Dr. Peng reviews the current ADC landscape and share key considerations and platform strategies to accelerate conjugation process development for next-gen ADCs.
The bioconjugate landscape is evolving beyond traditional ADCs toward next generation ADCs such as bispecific ADCs and dual payload ADCs. While these modalities expand therapeutic potential, they also introduce more complex CMC requirements in conjugation process development, including tighter control of DAR profiles, intermediate stability, impurity clearance, and process scalability.
Using practical examples, the session covers how to design and optimize site-specific conjugation process, how to develop stepwise, in-process-control (IPC) strategies for dual-payload ADCs, and how to improve impurity control for novel payload linkers.
Key Topics Include:
- Understand the current ADC landscape and key trends in next-gen ADCs
- Identify the major CMC challenges introduced by next-gen ADC designs
- Explain the development strategies for site specific conjugation processes
- Apply IPC strategies to support step wise development of complex conjugation processes
- Evaluate impurity removal strategy for novel payload linkers
Presenters
Director
ADC Conjugation Process Development
AsymBio
Dr. Qiang Peng leads the conjugation process development team at AsymBio, with hands-on experience spanning both stochastic conjugation and advanced site-specific technologies.
Webinar Host
AsymBio
AsymBio is a technology-driven global CDMO specializing in biologics, bioconjugates (ADCs, AOCs, PDCs, RDCs), antibodies and recombinant proteins. We deliver comprehensive end-to-end CDMO services from early-stage R&D to commercial-scale manufacturing, backed by GMP-compliant facilities meeting US, EU and China standards.
Additional Content From AsymBio
ADC Payload-Linker CMC Process Development Strategy
Hear Dr. Zheng Wei share a comprehensive payload-linker CMC development strategy that covers regulatory guidance, RSM selection, and stage-appropriate quality control to navigate the evolving complexities of ADC design from IND to NDA.
ADCs on The Horizon: The Performance and Prospect of Cell Line Development Platform — AmigoCHO™
Dr. Jiawen Xu presents AsymBio’s AmigoCHO™ platform and "CLD toolbox" strategies designed to accelerate cell line development and overcome CMC bottlenecks for complex antibody and ADC programs.
Related Content
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.